SMART Therapy: Making a Science-Based Choice (AAN)
Price: FREE for members and non-members
Session recorded on April 18, 2023
Speaker: Len Bacharier, MD
SMART (Single Maintenance and Reliever Therapy) allows people with asthma to use just one medication for both maintenance and reliever therapy. Both NAEPP and GINA guidelines identify the role of this therapy in asthma management. Despite this, many providers are unfamiliar with the basis of this recommendation or how to implement it. In this webinar, attendees will learn how to implement MART in patients with asthma and how to develop action plans using MART.
Viewers can earn credit by completing the posttest questions.
This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Allied Health Professionals
Upon completion of this activity, learners should be able to:
- Explain the basis of anti-inflammatory reliever therapy, both as MART and as a reliever in mild asthma.
- Describe how to implement MART in patients with asthma.
- Develop action plans using MART.
All relevant financial relationships have been mitigated.
The individuals listed below disclose the following financial relationships:
Len Bacharier, MD
Advisor: Sanofi/Regeneron, GlaxoSmithKline, AstraZeneca, Avillion, DBV Tech, Vertex, OM Pharma, Recludix
Consultant: Sanofi/Regeneron, AstraZeneca, Avillion, Genentech
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance